<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328651</url>
  </required_header>
  <id_info>
    <org_study_id>XEJB_Ver1.0</org_study_id>
    <nct_id>NCT02328651</nct_id>
  </id_info>
  <brief_title>Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease</brief_title>
  <official_title>Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weihai Rensheng Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <brief_summary>
    <textblock>
      This is a single-blinded randomized trial aiming to evaluate the effectiveness of Xiaoer
      Jiebiao Oral liquid in combination with Ribavirin treatment on patients with hand-foot-mouth
      disease compared with the controlgroup that recieve only libavirin treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (hours) taken from treatment start till body temperature dropping to normal</measure>
    <time_frame>time length( hours) from treatment starting to the time that body temperature drop to normal 37.0 degree for 12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time (hours) taken from disease onset till body temperature dropping to normal</measure>
    <time_frame>time length (hours) from the disease onset (the starting of fever) till the time that body temperature dropped to normal (37.0 degree) and lasting for at least 12 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Top body temperature at the 24th hour, 48th hour and the 72th hour from treatment starting.</measure>
    <time_frame>from starting of treatment to the 24th hour, 48th hour, and the 72th hour</time_frame>
    <description>top body temperature at 3 time points after treatment diarrhea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse digestive tract symptoms</measure>
    <time_frame>from start of treatment to discharge</time_frame>
    <description>proportion of patients with digestive tract symptoms during treatment, such as vomit, abdomial pain or diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal blood routine</measure>
    <time_frame>from the start of treatment to discharge test</time_frame>
    <description>defined as 1 if any abnormal blood routine occur, otherwise defined as 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal Urine routine</measure>
    <time_frame>from the start of treatment to discharge</time_frame>
    <description>defined as 1 if any liver function examination or kidney function examination occur, otherwise defined as 0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">398</enrollment>
  <condition>Handfoot-mouth Disease</condition>
  <arm_group>
    <arm_group_label>Ribavirin treatment plus testing drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribavirin treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin plus Xiao'er jiebiao oral liquid</intervention_name>
    <description>For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.
For moderate (Phase II) patients:
recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg,iv, Bid~tid）</description>
    <arm_group_label>Ribavirin treatment plus testing drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.
For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg, iv, Bid~tid）</description>
    <arm_group_label>Ribavirin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:subjects should meet all of the following

          -  diagnosed as hand-foot-mouth disease grade I or grade II;

          -  body temperature at admission T&gt;38℃，fever length&lt;48 hours;

          -  no need for hormonotherapy or immunoglobulin therapy.

          -  signed written informed consent form

        Exclusion Criteria:subjects should be excluded if meet any of the following

          -  with history of any heart, lung, kidney or liver diseases; under any hormonotherapy,
             immunoglobulin therapy or any other therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui Yu, MD PhD</last_name>
    <phone>+86 21 64931184</phone>
    <email>yuhui4756@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Yu</last_name>
      <phone>+86 21 64931215</phone>
      <email>yuhui4756@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Hui Yu</investigator_full_name>
    <investigator_title>Professor, Director</investigator_title>
  </responsible_party>
  <keyword>Mild and Moderate Severe Patients With hand_foot-mouth Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Diseases</mesh_term>
    <mesh_term>Foot-and-Mouth Disease</mesh_term>
    <mesh_term>Hand, Foot and Mouth Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

